(Formerly AMAG Pharmaceuticals until acquisition in November 2020)Lead Market Access group supporting Specialty products (Medical and Pharmacy Benefit) for Hematology/Oncology, Respiratory, Maternal Health, and established brands.- Strategic Accounts group manages "Buy and Bill" contracting/reimbursement for Hem/Onc and Hospitals- Managed Care group manages Medical and Pharmacy benefit contracting with PBMs/Payers- Trade & Distribution group manages Specialty Pharmacy/Distributor and Wholesaler relations- Pricing & Contracting group manages ASP/WAC pricing and all Contracting efforts- Patient Services group manages 2 HUB programs for specialty products

Led Market Access and Marketing activities for 3 rare disease indications (FA - Friedreich's Ataxia, Alport Syndrome, and Pulmonary Arterial Hypertension associated with Connective Tissue Disease). - (Fully focused on Market Access as of 6/2018)Market Access: - Developed value propositions for brands - Developed HEOR evidence generation plan in collaboration with Medical - Conducted pricing research to develop launch pricing assumptions - Developed distribution (SP network) and HUB model strategyMarketing: - Led commercial marketing strategy development for 3 rare / orphan indications - Close collaborations with Medical Affairs, Regulatory, Patient Advocacy, Legal, and Clinical - Conducted extensive market research (Patient Journey, Predictive Modeling, etc...) to build insights - Developed multi-year staffing and budgets to support commercialization

Lead a team of National Account and Regional Account Managers covering ~70% of lives in the US. Responsible for Contracting, Access creation, and Sales to Optum/UHC, ESI, CVS, Humana, Kaiser, Anthem, MedImpact, HealthNet and regional accounts in the Western US.

Lead a team of National Account Directors and Strategic Account Executives responsible for contracting, sales, and account management with Payers and Integrated Delivery Networks. Payer lead for OFEV launch for IPF (rare/orphan indication).NAD team manages all GPO contracting nationally (Vizient, Premier, MedAssets, Apexus, etc...). Account team covers: TX, AZ, CO, NV, LA, AL, MS, AR, OK, NM, UT, WY, MT and uses a collaborative approach with Regional Health Systems, IDN's and large Provider groups to align payer and provider strategies to address gaps in care in Respiratory disease, Diabetes, CV disease, and Anti-Coagulation.* Successfully launched 6 Brands and executed additional line-extensions* Lead strategic engagement of Sales to drive pull-through in key markets * Lead strategic contracting activities for Institutional Sales channel* Lead projects to maximize end of lifecycle revenue for assets* Lead development of advanced Key Account Management training * Serve as lead Managed Markets Director for Specialty product portfolio

Global Brand leader for interferon-free HCV asset. Led all marketing activities in preparation for launch including commercial strategy development, positioning, forecasting, communications strategy, packaging development, etc...* Led the development of customized forecasting model* Led market research to inform multiple launch strategies * Managed numerous vendor relationships, budgets, timelines, and deliverables

Led global market access activities for wide range of assets in Oncology, Diabetes, Immunology, CNS. * Led a global project restructuring the process for inclusion of Market Access insights into clinical development* Led the global market access strategy development for late-stage diabetes asset* Served on the Core Clinical Development team responsible for all asset development activities including Regulatory, Medical, Commercial and Manufacturing* Led the global market access strategy development for late-stage oncology asset* Led the development of International price referencing tool to optimize launch sequence and profitability* Led early asset valuation projects in multiple therapeutic areas* Led global market research projects to gain customer insights to inform strategic plans